Healthcare provider profile · identity verified

Timothy Samuel Johnson, MD

Allopathic & Osteopathic Physicians|Family Medicine · ATKINS, AR · NPI 1023074119

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Timothy Samuel Johnson, MD received $15.84 in general payments during 2025 across 1 reported records.

ABBVIE INC. accounted for 100.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 1 associated product.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Linzess by this doctor in 2024.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Synthroid by this doctor in 2024.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$15.84

1 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
ABBVIE INC.	Unresolved — no canonical attribution shown	$15.84	100.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$15.84	1

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
MAVYRET Normalized: mavyret	Drug	ABBVIE INC.	$15.84	1	2025
Source payment records 2025-07-17 · ABBVIE INC. · $15.84 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
ABBVIE INC. Exact reporting entity; no affiliate inference	2025	LINZESS open payments reported associated product	CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608	Linzess · 2024 Exact normalized brand match · 1 Part D row	31	suppressed by CMS
ABBVIE INC. Exact reporting entity; no affiliate inference	2025	SYNTHROID open payments reported associated product	CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636	Synthroid · 2024 Exact normalized brand match · 1 Part D row	54	11
ABBVIE INC. Exact reporting entity; no affiliate inference	2025	VRAYLAR open payments reported associated product	CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550	Vraylar · 2024 Exact normalized brand match · 1 Part D row	12	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	586	117
Atorvastatin Calcium	Atorvastatin Calcium	534	136
Lisinopril	Lisinopril	423	111
Metformin Hcl	Metformin Hcl	368	90
Gabapentin	Gabapentin	367	80
Amlodipine Besylate	Amlodipine Besylate	360	95
Duloxetine Hcl	Duloxetine Hcl	354	66
Pantoprazole Sodium	Pantoprazole Sodium	346	96
Simvastatin	Simvastatin	301	70
Losartan Potassium	Losartan Potassium	277	77
Omeprazole	Omeprazole	277	69
Tamsulosin Hcl	Tamsulosin Hcl	202	44
Albuterol Sulfate Hfa	Albuterol Sulfate	190	49
Glimepiride	Glimepiride	181	48
Meloxicam	Meloxicam	179	48
Hydrochlorothiazide	Hydrochlorothiazide	175	52
Jardiance	Empagliflozin	166	30
Rosuvastatin Calcium	Rosuvastatin Calcium	165	47
Mounjaro	Tirzepatide	164	28
Atenolol	Atenolol	163	41
Metoprolol Succinate	Metoprolol Succinate	155	40
Sertraline Hcl	Sertraline Hcl	151	36
Famotidine	Famotidine	139	33
Allopurinol	Allopurinol	134	36
Tizanidine Hcl	Tizanidine Hcl	133	36
Eliquis	Apixaban	131	22
Tramadol Hcl	Tramadol Hcl	131	33
Trazodone Hcl	Trazodone Hcl	130	31
Escitalopram Oxalate	Escitalopram Oxalate	125	28
Furosemide	Furosemide	125	39
Metoprolol Tartrate	Metoprolol Tartrate	125	34
Nifedipine Er	Nifedipine	125	30
Carvedilol	Carvedilol	121	33
Citalopram Hbr	Citalopram Hydrobromide	115	27
Montelukast Sodium	Montelukast Sodium	113	31
Ozempic	Semaglutide	109	21
Clopidogrel	Clopidogrel Bisulfate	108	29
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	106	25
Potassium Chloride	Potassium Chloride	103	30
Esomeprazole Magnesium	Esomeprazole Magnesium	102	16
Diclofenac Sodium	Diclofenac Sodium	99	41
Alendronate Sodium	Alendronate Sodium	95	31
Fluticasone Propionate	Fluticasone Propionate	91	25
Pravastatin Sodium	Pravastatin Sodium	91	22
Farxiga	Dapagliflozin Propanediol	88	22
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	88	19
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	86	22
Mirtazapine	Mirtazapine	86	18
Quetiapine Fumarate	Quetiapine Fumarate	83	14
Valsartan	Valsartan	77	25
Bupropion Xl	Bupropion Hcl	73	15
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	67	22
Doxycycline Hyclate	Doxycycline Hyclate	67	47
Fluoxetine Hcl	Fluoxetine Hcl	66	12
Aripiprazole	Aripiprazole	63	11
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	62	16
Prednisone	Prednisone	61	44
Pregabalin	Pregabalin	60	15
Enalapril Maleate	Enalapril Maleate	58	15
Spironolactone	Spironolactone	58	17
Tresiba Flextouch U-200	Insulin Degludec	58	suppressed
Warfarin Sodium	Warfarin Sodium	57	14
Shingrix	Varicella-Zoster Ge/As01b/Pf	56	42
Fenofibrate	Fenofibrate	54	12
Olanzapine	Olanzapine	54	suppressed
Synthroid	Levothyroxine Sodium	54	11
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	53	11
Venlafaxine Hcl Er	Venlafaxine Hcl	49	12
Tresiba Flextouch U-100	Insulin Degludec	48	11
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	47	12
Xarelto	Rivaroxaban	47	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	45	suppressed
Ezetimibe	Ezetimibe	44	12
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	44	11
Alprazolam	Alprazolam	43	11
Lorazepam	Lorazepam	43	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	42	33
Pioglitazone Hcl	Pioglitazone Hcl	42	11
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	42	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	40	11
Novolog Flexpen	Insulin Aspart	39	13
Primidone	Primidone	39	suppressed
Benazepril Hcl	Benazepril Hcl	38	suppressed
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	38	13
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	37	37
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	37	suppressed
Ondansetron Odt	Ondansetron	37	23
Clonazepam	Clonazepam	36	suppressed
Glipizide	Glipizide	35	suppressed
Breo Ellipta	Fluticasone/Vilanterol	34	suppressed
Ropinirole Hcl	Ropinirole Hcl	34	suppressed
Clonidine Hcl	Clonidine Hcl	33	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	33	suppressed
Sucralfate	Sucralfate	32	11
Acyclovir	Acyclovir	31	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	31	suppressed
Celecoxib	Celecoxib	31	11
Linzess	Linaclotide	31	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	31	11
Chlorthalidone	Chlorthalidone	30	suppressed
Imipramine Hcl	Imipramine Hcl	30	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	29	23
Fenofibrate	Fenofibrate,micronized	29	suppressed
Topiramate	Topiramate	29	suppressed
Risperidone	Risperidone	28	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	28	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	27	suppressed
Fluconazole	Fluconazole	27	15
Metformin Hcl Er	Metformin Hcl	27	suppressed
Hydralazine Hcl	Hydralazine Hcl	26	suppressed
Propranolol Hcl Er	Propranolol Hcl	26	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	25	suppressed
Januvia	Sitagliptin Phosphate	25	suppressed
Paroxetine Hcl	Paroxetine Hcl	25	suppressed
Propranolol Hcl	Propranolol Hcl	25	suppressed
Ventolin Hfa	Albuterol Sulfate	25	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	22	suppressed
Methenamine Hippurate	Methenamine Hippurate	21	suppressed
Amiodarone Hcl	Amiodarone Hcl	20	suppressed
Droplet Pen Needle	Pen Needle, Diabetic	20	suppressed
Dropsafe Prep Pads	Alcohol Antiseptic Pads	20	suppressed
Spiriva Respimat	Tiotropium Bromide	20	suppressed
Terazosin Hcl	Terazosin Hcl	20	suppressed
Memantine Hcl	Memantine Hcl	19	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	19	suppressed
Advair Diskus	Fluticasone Propion/Salmeterol	18	suppressed
Baclofen	Baclofen	18	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	18	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	18	suppressed
Levemir Flexpen	Insulin Detemir	18	suppressed
Levetiracetam	Levetiracetam	18	suppressed
Nitroglycerin	Nitroglycerin	18	11
Oxybutynin Chloride Er	Oxybutynin Chloride	18	suppressed
Bevespi Aerosphere	Glycopyrrolate/Formoterol Fum	17	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	17	suppressed
Donepezil Hcl	Donepezil Hcl	17	suppressed
Myrbetriq	Mirabegron	17	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	16	15
Amantadine	Amantadine Hcl	16	suppressed
Humalog Kwikpen U-100	Insulin Lispro	16	suppressed
Nystatin	Nystatin	16	11
Promethazine Hcl	Promethazine Hcl	16	suppressed
Buspirone Hcl	Buspirone Hcl	15	suppressed
Cephalexin	Cephalexin	15	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	15	12
Doxazosin Mesylate	Doxazosin Mesylate	15	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	15	suppressed
Ipratropium Bromide	Ipratropium Bromide	15	suppressed
Nebivolol Hcl	Nebivolol Hcl	15	suppressed
Testosterone	Testosterone	15	suppressed
Atrovent Hfa	Ipratropium Bromide	14	suppressed
Doxepin Hcl	Doxepin Hcl	14	suppressed
Irbesartan	Irbesartan	14	suppressed
Novolog	Insulin Aspart	14	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	14	14
Trulicity	Dulaglutide	14	suppressed
Isosorbide Dinit-Hydralazine	Isosorbide Dinit/Hydralazine	13	suppressed
Janumet Xr	Sitagliptin Phos/Metformin Hcl	13	suppressed
Ranolazine Er	Ranolazine	13	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	13	suppressed
Advocate Pen Needles	Pen Needle, Diabetic	12	suppressed
Azelastine Hcl	Azelastine Hcl	12	suppressed
Benztropine Mesylate	Benztropine Mesylate	12	suppressed
Enalapril-Hydrochlorothiazide	Enalapril/Hydrochlorothiazide	12	suppressed
Finasteride	Finasteride	12	suppressed
Incruse Ellipta	Umeclidinium Bromide	12	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	12	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	12	suppressed
Vraylar	Cariprazine Hcl	12	suppressed
Cholestyramine Light	Cholestyramine	11	suppressed
Clindamycin Hcl	Clindamycin Hcl	11	suppressed
Eszopiclone	Eszopiclone	11	suppressed
Glipizide Er	Glipizide	11	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	11	suppressed
Naproxen	Naproxen	11	suppressed
Symbicort	Budesonide/Formoterol Fumarate	11	suppressed
Trospium Chloride Er	Trospium Chloride	11	suppressed
Valacyclovir	Valacyclovir Hcl	11	suppressed
Varenicline Tartrate	Varenicline Tartrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$15.84 · 1 records	ABBVIE INC.	MAVYRET	3	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error